0000899243-19-007818.txt : 20190314
0000899243-19-007818.hdr.sgml : 20190314
20190314212523
ACCESSION NUMBER: 0000899243-19-007818
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190313
FILED AS OF DATE: 20190314
DATE AS OF CHANGE: 20190314
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Ragan Paula
CENTRAL INDEX KEY: 0001769914
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38295
FILM NUMBER: 19682702
MAIL ADDRESS:
STREET 1: C/O X4 PHARMACEUTICALS, INC.
STREET 2: 955 MASSACHUSETTS AVE., 4TH FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: X4 Pharmaceuticals, Inc
CENTRAL INDEX KEY: 0001501697
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 273181608
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 955 MASSACHUSETTS AVENUE
STREET 2: 4TH FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 857-529-8300
MAIL ADDRESS:
STREET 1: 955 MASSACHUSETTS AVENUE
STREET 2: 4TH FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
FORMER COMPANY:
FORMER CONFORMED NAME: Arsanis, Inc.
DATE OF NAME CHANGE: 20100920
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2019-03-13
0
0001501697
X4 Pharmaceuticals, Inc
XFOR
0001769914
Ragan Paula
C/O X4 PHARMACEUTICALS, INC.
955 MASSACHUSETTS AVENUE, 4TH FLOOR
CAMBRIDGE
MA
02139
1
1
0
0
President and CEO
Common Stock
2019-03-13
4
A
0
181366
A
181366
D
Stock Option (right to buy)
6.84
2019-03-13
4
A
0
100729
A
2026-01-18
Common Stock
100729
100729
D
Stock Option (right to buy)
6.84
2019-03-13
4
A
0
65430
A
2027-01-23
Common Stock
65430
65430
D
Stock Option (right to buy)
7.08
2019-03-13
4
A
0
80160
A
2028-01-30
Common Stock
80160
80160
D
Received in exchange for 1,870,000 shares of common stock of X4 Therapeutics, Inc. (formerly X4 Pharmaceuticals, Inc.) ("X4") and 38,451 shares of Series Seed preferred stock of X4 in connection with the merger of Artemis AC Corp., a wholly-owned subsidiary of the Issuer, with and into X4 (the "Merger") on March 13, 2019.
Fully vested.
Reflects the Reporting Person's stock option to acquire 1,059,935 shares of X4 common stock for $0.65 per share that was assumed by the Issuer in the Merger.
Twenty-five percent (25%) of the shares subject to the option vested on January 24, 2018, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date.
Reflects the Reporting Person's stock option to acquire 688,500 shares of X4 common stock for $0.65 per share that was assumed by the Issuer in the Merger.
Twenty-five percent (25%) of the shares subject to the option vested on January 31, 2019, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date.
Reflects the Reporting Person's stock option to acquire 843,496 shares of X4 common stock for $0.67 per share that was assumed by the Issuer in the Merger.
All share and per share amounts of the Issuer's common stock and stock options reported in this Form 4 reflect the 1-for-6 reverse stock split of the Issuer's common stock effected on March 13, 2019 after the completion of the Merger.
/s/ Adam S. Mostafa, attorney-in-fact
2019-03-14